SG11201900681SA - Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors - Google Patents
Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitorsInfo
- Publication number
- SG11201900681SA SG11201900681SA SG11201900681SA SG11201900681SA SG11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA SG 11201900681S A SG11201900681S A SG 11201900681SA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- hyderabad
- serene
- life sciences
- avenue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028166 | 2016-08-18 | ||
| PCT/IB2017/054938 WO2018033847A1 (en) | 2016-08-18 | 2017-08-14 | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900681SA true SG11201900681SA (en) | 2019-02-27 |
Family
ID=59887325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900681SA SG11201900681SA (en) | 2016-08-18 | 2017-08-14 | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10603323B2 (zh) |
| EP (1) | EP3500253B1 (zh) |
| JP (1) | JP6734470B2 (zh) |
| KR (1) | KR102039585B1 (zh) |
| CN (1) | CN109640975B (zh) |
| AU (1) | AU2017313427B2 (zh) |
| BR (1) | BR112019002645A2 (zh) |
| CA (1) | CA3033039C (zh) |
| CY (1) | CY1123238T1 (zh) |
| DK (1) | DK3500253T3 (zh) |
| EA (1) | EA032957B1 (zh) |
| ES (1) | ES2810983T3 (zh) |
| HR (1) | HRP20201262T1 (zh) |
| HU (1) | HUE052003T2 (zh) |
| IL (1) | IL264406B (zh) |
| LT (1) | LT3500253T (zh) |
| MA (1) | MA45990B1 (zh) |
| MD (1) | MD3500253T2 (zh) |
| ME (1) | ME03812B (zh) |
| MX (1) | MX2019001696A (zh) |
| NZ (1) | NZ750150A (zh) |
| PL (1) | PL3500253T3 (zh) |
| PT (1) | PT3500253T (zh) |
| RS (1) | RS60669B1 (zh) |
| SG (1) | SG11201900681SA (zh) |
| SI (1) | SI3500253T1 (zh) |
| WO (1) | WO2018033847A1 (zh) |
| ZA (1) | ZA201900467B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52850A (fr) * | 2018-05-31 | 2021-04-21 | Suven Life Sciences Ltd | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120035183A (ko) * | 2009-06-10 | 2012-04-13 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| SI2694492T1 (sl) * | 2011-02-23 | 2015-11-30 | Suven Life Sciences Limited | Nove spojine kot ligandi histaminskega receptorja H3 |
| FR2974729B1 (fr) | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| SG11201601306QA (en) | 2013-09-09 | 2016-03-30 | Sanofi Sa | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
-
2017
- 2017-08-14 WO PCT/IB2017/054938 patent/WO2018033847A1/en active Search and Examination
- 2017-08-14 HU HUE17768234A patent/HUE052003T2/hu unknown
- 2017-08-14 PT PT177682341T patent/PT3500253T/pt unknown
- 2017-08-14 RS RS20200949A patent/RS60669B1/sr unknown
- 2017-08-14 MX MX2019001696A patent/MX2019001696A/es active IP Right Grant
- 2017-08-14 ES ES17768234T patent/ES2810983T3/es active Active
- 2017-08-14 SG SG11201900681SA patent/SG11201900681SA/en unknown
- 2017-08-14 CA CA3033039A patent/CA3033039C/en active Active
- 2017-08-14 PL PL17768234T patent/PL3500253T3/pl unknown
- 2017-08-14 ME MEP-2020-167A patent/ME03812B/me unknown
- 2017-08-14 LT LTEP17768234.1T patent/LT3500253T/lt unknown
- 2017-08-14 MD MDE20190714T patent/MD3500253T2/ro unknown
- 2017-08-14 BR BR112019002645A patent/BR112019002645A2/pt active Search and Examination
- 2017-08-14 EP EP17768234.1A patent/EP3500253B1/en active Active
- 2017-08-14 US US16/320,949 patent/US10603323B2/en active Active
- 2017-08-14 MA MA45990A patent/MA45990B1/fr unknown
- 2017-08-14 EA EA201990480A patent/EA032957B1/ru unknown
- 2017-08-14 KR KR1020197007056A patent/KR102039585B1/ko active IP Right Grant
- 2017-08-14 SI SI201730360T patent/SI3500253T1/sl unknown
- 2017-08-14 JP JP2019506640A patent/JP6734470B2/ja active Active
- 2017-08-14 DK DK17768234.1T patent/DK3500253T3/da active
- 2017-08-14 AU AU2017313427A patent/AU2017313427B2/en active Active
- 2017-08-14 CN CN201780049311.9A patent/CN109640975B/zh active Active
- 2017-08-14 NZ NZ750150A patent/NZ750150A/en unknown
-
2019
- 2019-01-22 IL IL264406A patent/IL264406B/en active IP Right Grant
- 2019-01-23 ZA ZA2019/00467A patent/ZA201900467B/en unknown
-
2020
- 2020-08-05 CY CY20201100725T patent/CY1123238T1/el unknown
- 2020-08-11 HR HRP20201262TT patent/HRP20201262T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201900269XA (en) | Channel sensing for independent links | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |